Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by Creative Planning

Creative Planning raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 5.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,382 shares of the company’s stock after purchasing an additional 1,522 shares during the period. Creative Planning’s holdings in Ionis Pharmaceuticals were worth $1,137,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. nVerses Capital LLC acquired a new stake in Ionis Pharmaceuticals in the second quarter worth about $29,000. GAMMA Investing LLC grew its position in Ionis Pharmaceuticals by 83.9% during the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in Ionis Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Mather Group LLC. raised its holdings in shares of Ionis Pharmaceuticals by 35.8% in the second quarter. Mather Group LLC. now owns 911 shares of the company’s stock worth $39,000 after buying an additional 240 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in shares of Ionis Pharmaceuticals by 948.8% during the first quarter. Advisors Asset Management Inc. now owns 3,178 shares of the company’s stock worth $138,000 after buying an additional 2,875 shares during the period. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on IONS shares. Barclays lifted their price target on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. BMO Capital Markets lowered Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $67.00 to $60.00 in a research report on Friday, August 2nd. Guggenheim cut their price target on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Bank of America upped their price objective on shares of Ionis Pharmaceuticals from $67.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group initiated coverage on shares of Ionis Pharmaceuticals in a report on Tuesday, July 16th. They set a “buy” rating and a $75.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $60.28.

Insider Buying and Selling

In related news, EVP Richard S. Geary sold 2,430 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $48.00, for a total transaction of $116,640.00. Following the completion of the sale, the executive vice president now directly owns 85,508 shares in the company, valued at approximately $4,104,384. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders have sold 2,803 shares of company stock worth $134,402. 2.71% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Stock Performance

IONS opened at $38.39 on Friday. Ionis Pharmaceuticals, Inc. has a 52-week low of $35.95 and a 52-week high of $54.44. The company has a quick ratio of 7.51, a current ratio of 7.61 and a debt-to-equity ratio of 4.67. The firm’s fifty day simple moving average is $41.96 and its two-hundred day simple moving average is $43.04. The company has a market cap of $5.61 billion, a price-to-earnings ratio of -15.23 and a beta of 0.38.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative return on equity of 115.66% and a negative net margin of 44.90%. The firm had revenue of $225.00 million during the quarter, compared to the consensus estimate of $152.35 million. During the same period in the prior year, the company earned $0.60 EPS. The firm’s revenue was up 19.7% compared to the same quarter last year. Equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.67 earnings per share for the current fiscal year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.